Physician profile
Oscar B Goodman
NPI 1568542108
$211,370.64
in general payments reported to CMS, 2019-2025
40 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $17K · 2021: $3,468 · 2022: $29K · 2023: $35K · 2024: $16K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Consulting Fee: $33K · Travel and Lodging: $11K · Food and Beverage: $6,475 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,570.13 |
| Consulting Fee | $32,913.00 |
| Travel and Lodging | $11,128.25 |
| Food and Beverage | $6,475.26 |
| Education | $122.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $65,728.83 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $55,838.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $31,164.38 | 2020-2025 | Lynparza, Imfinzi |
| Eisai INC. | $18,300.48 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $17,234.06 | 2025 | Provenge |
| Seagen INC. | $7,630.00 | 2019 | |
| Exelixis INC. | $2,324.63 | 2021-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $2,196.73 | 2025 | Jemperli |
| Astellas Pharma Global Development | $2,187.50 | 2022 | |
| Janssen Global Services, LLC | $2,161.25 | 2020 | |
| Janssen Research & Development, LLC | $1,395.50 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $1,050.00 | 2022 | |
| Daiichi Sankyo INC. | $840.59 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Janssen Scientific Affairs, LLC | $817.50 | 2023 | |
| Novartis Pharmaceuticals Corporation | $505.15 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $343.71 | 2023-2025 | |
| Astellas Pharma US INC | $310.74 | 2023-2025 | Xtandi, Xospata, Padcev |
| Bioprotect Medical, INC. | $257.58 | 2025 | Bioprotect Balloon Implant System |
| Merck Sharp & Dohme LLC | $163.17 | 2022-2024 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $140.42 | 2020-2025 | Opdivo, Opdualag |
| Urogen Pharma, INC. | $125.00 | 2022 | |
| Tempus Ai, INC | $123.78 | 2024-2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $118.54 | 2023-2025 | Orgovyx |
| Celgene Corporation | $95.59 | 2022-2024 | Reblozyl |
| Array Biopharma INC | $74.78 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Accord Healthcare, INC. | $37.15 | 2024-2025 | |
| Genzyme Corporation | $33.48 | 2023 | |
| Jazz Pharmaceuticals INC. | $23.56 | 2025 | |
| Beigene USA, INC. | $21.31 | 2025 | Brukinsa |
| Emd Serono, INC. | $20.93 | 2025 | |
| Servier Pharmaceuticals LLC | $19.83 | 2023 | |
| Mirati Therapeutics, INC. | $17.49 | 2024 | Krazati |
| Springworks Therapeutics, INC. | $16.32 | 2024 | Ogsiveo |
| Octapharma USA, INC. | $15.12 | 2023 | Octagam Immune Globulin (Human) |
| Regeneron Healthcare Solutions, INC. | $14.23 | 2023 | Libtayo |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.00 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.